PDCD1 and neoplasm: They also showed that systemic delivery of soluble IL-21 did not improve the therapeutic efficacy of PD-1 blockade, however when the anti-PD-1 antibody was fused to IL-21 synergetic improvement in tumor immunity was noticed (139, 140).